Treatment guidelines for COVID-19 infected patients
Medicina Interna de Mexico
; 34(4):509-529, 2021.
Article
in Spanish
| Scopus | ID: covidwho-1068234
ABSTRACT
BACKGROUND:
New information for potential treatments against SARS-CoV-2 is rapidly increasing. As a result, countries and organizations have begun to release therapeutic guidelines.OBJECTIVE:
To provide a synopsis of the recommendations supported in evidence-based guidelines for therapeutic options with potential activity against SARS-CoV-2.METHOD:
Rapid systematic review of guidelines and/or protocols that provide interim clinical guidance for COVID-19 disease were extracted from PubMed/Medline, Web of Science, Scopus, Scielo, Google Scholar, and a general Google search. Duplicates were removed and a summary of the proposed interventions was included. A benefit risk analysis was then conducted.RESULTS:
Twenty guidelines and/or protocols were selected;the majority of which came from Europe and Latin America. Seventeen interventions were identified and classified into 6 pharmacological groups. Antimalarials, lopinavir/ritonavir and remdesivir were the only agents recommended and supported by clinical trials. The remaining interventions were recommended based on indirect evidence, observational studies, or in vitro studies.CONCLUSIONS:
Antimalarials have shown results against COVID-19 with surrogate outcomes and the presence of serious adverse events. We recommend active monitoring of agents with potential efficacy against SARS-CoV-2 and incorporating the results in national guidelines and protocols. Clinical trials should be conducted to show direct benefit with clinically relevant outcomes in various populations. © 2020 Comunicaciones Cientificas Mexicanas S.A. de C.V.. All rights reserved.
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Language:
Spanish
Journal:
Medicina Interna de Mexico
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS